ESMO Virtual Plenary on-demand resources

Virtual Plenary: 27-28 March 2023

Immunotherapy+chemotherapy for the treatment of primary advanced or recurrent endometrial cancer: The placebo-controlled randomised phase III RUBY trial

Presenter: Mansoor Mirza, Denmark; Discussant: Ilaria Colombo, Switzerland; AACR expert commentary: Elise C. Kohn, USA

Virtual Plenary: 16-17 February 2023

Immunotherapy plus chemotherapy as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction cancer: Phase III KEYNOTE-859 study

Presenter: Sun Young Rha, Republic of Korea; Discussant: Elizabeth Smyth, UK; AACR expert commentary: Brian S. Henick, USA

Virtual Plenary: 15-16 December 2022

The NORA Trial: PARP inhibitor with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer, ad hoc interim overall survival results

Presenter: Mansoor Mirza, Denmark; Discussant: Antonio González-Martín, Spain

Virtual Plenary: 14-15 July 2022

Adjuvant immunotherapy combination in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up

Presenter: Sibylle Loibl, Germany; Discussant: Javier Cortés, Spain;

Virtual Plenary: 19-20 May 2022

Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of immunotherapy combination (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Presenter: Philippe Moreau, France; Discussant: Francesca Gay, Italy;

Virtual Plenary: 17-18 March 2022

Immunotherapy versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

Presenter: Luis Paz-Ares, Spain; Discussant: Martin Reck, Germany;

Virtual Plenary: 17-18 March 2022

Prospective double-blind, randomized phase III ENGOT-EN5/GOG-3055/SIENDO study of oral selective inhibitors of nuclear export/placebo as maintenance therapy after first-line chemotherapy for advanced or recurrent endometrial cancer

Presenter: Ignace Vergote, Belgium; Discussant: Amit Oza, Canada;

Virtual Plenary: 16-17 March 2022

Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant PARP inhibitor in germline BRCA1/2 mutation (gBRCAm) associated breast cancer

Presenter: Andrew Tutt, UK; Discussant: Mark Robson, USA;

Virtual Plenary: 16-17 December 2021

Combined chemotherapy plus immunotherapy as first line treatment for patients with metastatic colorectal cancer (mCRC) ineligible for intensive therapy: The phase III randomized SOLSTICE study

Presenter: Thierry André, France; Discussant: Demetris Papamichael, Cyprus;

Virtual Plenary: 20 November, from ESMO ASIA VIRTUAL ONCOLOGY WEEK 2021

TKI plus immunotherapy as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Presenter: Robin Kate Kelley, San Francisco, USA; Discussant: Ian Chau, Sutton, UK;

Virtual Plenary: 19 November, from ESMO ASIA VIRTUAL ONCOLOGY WEEK 2021

ORIENT-31: Phase III study of immune checkpoint inhibitor with or without anti-angiogenic therapy plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy

Presenter: Shun Lu, Shanghai, China; Discussant: Myung-Ju Ahn, Seoul, Republic of Korea (South Korea);

Virtual Plenary: 14-15 October 2021

Adjuvant kinase inhibitor Combined with Endocrine Therapy (ET) in Early Breast Cancer: Updated Results from MonarchE

Presenter: Joyce O'Shaughnessy, USA; Discussant: Aditya Bardia, USA;

Virtual Plenary: 15-16 July 2021

KEYNOTE-522: Phase III study of neoadjuvant immunotherapy + chemotherapy vs. placebo + chemotherapy, followed by adjuvant immunotherapy vs. placebo for early-stage TNBC

Presenter: Peter Schmid, UK; Discussant: Giuseppe Curigliano, Italy;

Virtual Plenary: 17-18 June 2021

IMpassion050: A phase 3 study of neoadjuvant immunotherapy triplet + chemotherapy in high-risk, HER2-positive early breast cancer

Presenter: Jens Huober, Switzerland; Discussant: Evandro de Azambuja, Belgium;

Virtual Plenary: 17-18 June 2021

IMpower133: Gene expression analysis in long-term survivors with ES-SCLC treated with first-line chemotherapy + immunotherapy

Presenter: Stephen Liu, USA; Discussant: Anne-Marie Dingemans, the Netherlands;

Virtual Plenary: 12-13 May 2021

Randomised Phase III Trial Data on the Efficacy and Safety of immunotherapy as Opposed to Chemotherapy in Patients with Progressive Advanced Cervical Cancer

Presenter: Krishnansu S. Tewari, USA; Discussant: Mansoor Mirza, Denmark;

Virtual Plenary: 12-13 May 2021

Randomised Phase II Trial Data on the Combination of 2nd-line Kinase Inhibitor (KI) and Immunotherapy Versus Standard of Care KI in EGFR T790M-mutated Advanced NSCLC

Presenter: Ross Soo, Singapore; Discussant: Edward Garon, USA;

Virtual Plenary: 8-9 Apr 2021

Effectiveness of immunotherapy alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data

Presenter: Solange Peters, Switzerland; Discussant: Federico Cappuzzo, Italy;

Virtual Plenary: 19 Feb 2021

Efficacy of Kinase Inhibitor in Patients With HR+/HER2- High Risk Early Stage Breast Cancer

Presenter: Thomas Bachelot, France; Discussant: Peter Schmid, UK;